

AQ

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/057489 A2

- (51) International Patent Classification⁷: C12Q 1/68, A61P 35/00
- (21) International Application Number: PCT/US01/43039
- (22) International Filing Date:
9 November 2001 (09.11.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/250,358 1 December 2000 (01.12.2000) US
60/250,471 4 December 2000 (04.12.2000) US
09/877,178 11 June 2001 (11.06.2001) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- (71) Applicant: RESPONSE GENETICS, INC. [US/US];
1640 Marengo Street, 6th Floor, Los Angeles, CA 90033 (US).
- (72) Inventor: DANENBERG, Kathleen, D.; 3367 Rubio Crest Drive, Altadena, CA 91001 (US).
- (74) Agents: MELORO, Thomas, J. et al.; Kenyon & Kenyon, Suite 700, 1500 K Street N.W., Washington, DC 20005 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/057489 A2

(54) Title: METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON ERCC1 AND TS EXPRESSION

(57) Abstract: The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and/or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively.

METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON *ERCC1* and *TS* EXPRESSION

FIELD OF THE INVENTION

5 The present invention relates to prognostic methods which are useful in
medicine, particularly cancer chemotherapy. More particularly, the invention
relates to assessment of tumor cell gene expression in a patient. The resistance of
tumor cells to cytotoxic chemotherapeutic agents, especially antimetabolites and
agents that damage DNA in the manner of platinating agents is assayed by
10 examining the mRNA expressed from genes involved in nucleotide synthesis and
DNA repair in humans.

BACKGROUND OF THE INVENTION

Cancer arises when a normal cell undergoes neoplastic transformation and
becomes a malignant cell. Transformed (malignant) cells escape normal physiologic
15 controls specifying cell phenotype and restraining cell proliferation. Transformed
cells in an individual's body thus proliferate, forming a tumor. When a tumor is
found, the clinical objective is to destroy malignant cells selectively while mitigating
any harm caused to normal cells in the individual undergoing treatment.

Chemotherapy is based on the use of drugs that are selectively toxic
20 (cytotoxic) to cancer cells. Several general classes of chemotherapeutic drugs have
been developed, including drugs that interfere with nucleic acid synthesis, protein
synthesis, and other vital metabolic processes. These generally are referred to as

antimetabolite drugs. Other classes of chemotherapeutic drugs inflict damage on cellular DNA. Drugs of these classes generally are referred to as genotoxic.

Susceptibility of an individual neoplasm to a desired chemotherapeutic drug or combination of drugs often, however, can be accurately assessed only after a trial
5 period of treatment. The time invested in an unsuccessful trial period poses a significant risk in the clinical management of aggressive malignancies.

The repair of damage to cellular DNA is an important biological process carried out by a cell's enzymatic DNA repair machinery. Unrepaired lesions in a cell's genome can impede DNA replication, impair the replication fidelity of newly
10 synthesized DNA and/or hinder the expression of genes needed for cell survival. Thus, genotoxic drugs generally are considered more toxic to actively dividing cells that engage in DNA synthesis than to quiescent, nondividing cells. Normal cells of many body tissues, however, are quiescent and commit infrequently to re-enter the cell cycle and divide. Greater time between rounds of cell division generally is
15 afforded for the repair of DNA damage in normal cells inflicted by chemotherapeutic genotoxins. As a result, some selectivity is achieved for the killing of cancer cells. Many treatment regimes reflect attempts to improve selectivity for cancer cells by coadministering chemotherapeutic drugs belonging to two or more of these general classes.

20 Because effective chemotherapy in solid tumors often requires a combination of agents, the identification and quantification of determinants of resistance or sensitivity to each single drug has become an important tool to design individual combination chemotherapy.

Widely used genotoxic anticancer drugs that have been shown to damage
25 cellular DNA are cisplatin (DDP) and carboplatin. Cisplatin and/or carboplatin

currently are used in the treatment of selected, diverse neoplasms of epithelial and mesenchymal origin, including carcinomas and sarcomas of the respiratory, gastrointestinal and reproductive tracts, of the central nervous system, and of squamous origin in the head and neck. Cisplatin in combination with other agents is currently preferred for the management of testicular carcinoma, and in many instances produces a lasting remission. (Loehrer *et al.*, 1984, 100 Ann. Int. Med. 704). Cisplatin (DDP) disrupts DNA structure through formation of intrastrand adducts. Resistance to platinum agents such as DDP has been attributed to enhanced tolerance to platinum adducts, decreased drug accumulation, or enhanced DNA repair.

Oxaliplatin, another platinum-based chemotherapeutic agent carrying a 1,2-diaminocyclohexane ring has shown anti-tumor efficacy *in vitro* and *in vivo*. This bulky carrier group is considered to lead to platinum-DNA adducts, which are more cytotoxic than adducts formed from other platinum agents and more effective at blocking DNA replication. Recent data have shown that deficiency in the mismatch repair system (MMR) as well as increased ability of the replication complex to synthesize DNA past the site of DNA damage (enhanced replicative bypass) cause resistance to cisplatin, but not to oxaliplatin (Raymond *et al.*, Semin Oncol 25, Suppl 5: 4-12, 1998).

Excision repair of bulky DNA adducts, such as those formed by platinum agents, appears to be mediated by genes involved in DNA damage recognition and excision. Cleaver *et al.*, Carcinogenesis 11:875-882 (1990); Hoeijmakers *et al.*, Cancer Cells 2:311-320 (1990); Shivji *et al.*, Cell 69:367-374 (1992). Indeed, cells carrying a genetic defect in one or more elements of the enzymatic DNA repair

machinery are extremely sensitive to cisplatin. Fraval et al. (1978), 51 Mutat. Res. 121, Beck and Brubaker (1973), 116 J. Bacteriol 1247.

The excision repair cross-complementing (*ERCC1*) gene is essential in the repair of DNA adducts. The human *ERCC1* gene has been cloned. Westerveld et al.,
5 Nature (London) 310:425-428 (1984); Tanaka et al., Nature 348:73-76 (1990);
(Accession No. XM_009432, incorporated by reference herein with SEQ ID NO:
10). Several studies using mutant human and hamster cell lines that are defective in
this gene and studies in human tumor tissues indicate that the product encoded by
ERCC1 is involved in the excision repair of platinum-DNA adducts. Dabholkar et
10 al., J. Natl. Cancer Inst. 84:1512-1517 (1992); Dijt et al., Cancer Res. 48:6058-6062
(1988); Hansson et al., Nucleic Acids Res. 18: 35-40 (1990).

When transfected into DNA-repair deficient CHO cells, *ERCC1* confers
cellular resistance to platinum-based chemotherapy by its ability to repair platinum-
DNA adducts. Hansson et al., Nucleic Acids Res. 18: 35-40 (1990). Currently
15 accepted models of excision repair suggest that the damage recognition/excision step
is rate-limiting to the excision repair process.

The relative levels of expression of excision repair genes such as *ERCC1* in
malignant cells from cancer patients receiving platinum-based therapy has been
examined. Dabholkar et al., J. Natl. Cancer Inst. 84:1512-1517 (1992). *ERCC1*
20 overexpression in gastric cancer patients has been reported to have a negative impact
on tumor response and ultimate survival when treated with the combined platinum-
based and antimetabolite-based chemotherapeutic regimen (cisplatin/fluorouracil),
(Metzger, et al., J Clin Oncol 16: 309, 1998). Thus, intratumoral levels of *ERCC1*
expression may be a major prognostic factor for determining whether or not a

platinum-based chemotherapy either alone or combined with an antimetabolite-based therapy would be effective in treating cancer patients.

Antimetabolic cytotoxic chemotherapeutic compounds include drugs that interfere with nucleic acid synthesis, protein synthesis, and other vital metabolic processes. For example, 5-Fluorouracil (5-FU) is a very widely used drug used for the treatment of many different types of cancers, including major cancers such as those of the GI tract and breast (Moertel, C.G. *New Engl. J. Med.*, 330:1136-1142, 1994). 5-FU as a single agent was for more than 40 years the standard first-line treatment for colorectal cancer, but the combination of 5-FU and CPT-11 has recently been introduced as an alternative first-line therapy for advanced colorectal cancer (Saltz *et al.*, Irinotecan Study Group. *New England Journal of Medicine*. 343:905-14, 2000). The combination of 5-FU and oxaliplatin has produced high response rates in colorectal cancers (Raymond *et al.*, *Semin. Oncol.*, 25:4-12, 1998). Thus, it is likely that 5-FU will be used in cancer treatment for many years because it remains the central component of current chemotherapeutic regimens. In addition, single agent 5-FU therapy continues to be used for patients in whom combination therapy with CPT-11 or oxaliplatin is likely to be excessively toxic.

5-FU is typical of most anti-cancer drugs in that only the minority of patients experience a favorable response to the therapy. Large randomized clinical trials have shown the overall response rates of tumors to 5-FU as a single agent for patients with metastatic colorectal cancer to be in the 15-20% range (Moertel, C.G. *New Engl. J. Med.*, 330:1136-1142, 1994). In combination with other the chemotherapeutics mentioned above, tumor response rates to 5-FU-based regimens have been increased to almost 40%. Nevertheless, the majority of treated patients derive no tangible benefit from having received 5-FU based chemotherapy, and are

subjected to significant risk, discomfort, and expense. Since there has been no reliable means of anticipating the responsiveness of an individual's tumor prior to treatment, the standard clinical practice has been to subject all patients to 5-FU-based treatments, fully recognizing that the majority will suffer an unsatisfactory outcome.

The mechanism of action and the metabolic pathway of 5-FU have been intensively studied over the years to identify the most important biochemical determinants of the drug's anti-tumor activity. The ultimate goal was to improve the clinical efficacy of 5-FU by a) modulation of its intracellular metabolism and biochemistry and b) by measuring response determinants in patients' tumors prior to therapy to predict which patients are most likely to respond (or not to respond) to the drug.

The first studies in the area of tumor response prediction to 5-FU based therapy centered on its target enzyme, Thymidylate Synthase (TS), in colorectal cancer. TS has also been cloned. (Kaneda *et al.*, J. Biol. Chem. 265 (33), 20277-20284 (1990); Accession No. NM_001071, incorporated by reference herein with SEQ ID NO: 11). Leichman *et al.* (Leichman *et al.*, J. Clin Oncol., 15:3223-3229, 1997) carried out a prospective clinical trial to correlate tumor response to 5-FU with TS gene expression as determined by RT-PCR in pre-treatment biopsies from colorectal cancers. This study showed: 1) a large 50-fold range of TS gene expression levels among these tumors, and 2) strikingly different levels of TS gene expression between responding and non-responding tumors. The range of TS levels of the responding groups ($0.5-4.1 \times 10^{-3}$, relative to an internal control) was narrower than that of the non-responding groups ($1.6-23.0 \times 10^{-3}$, relative to an internal control). The investigators determined a resulting "non-response cutoff" threshold

level of *TS* expression above which there were only non-responders. Thus, patients with *TS* expression above this "non-response cutoff" threshold could be positively identified as non-responders prior to therapy. The "no response" classification included all therapeutic responses with <50% tumor shrinkage, progressing growth
5 resulting in a >25% tumor increase and non-progressing tumors with either <50% shrinkage, no change or <25% increase. These tumors had the highest *TS* levels. Thus, high *TS* expression identifies especially resistant tumors. *TS* expression levels above a certain threshold identified a subset of tumors not responding to 5-FU, whereas *TS* expression levels below this number predicted an appreciably higher
10 response rate.

Interestingly, Papamichael et al., has concluded that oxaliplatin enhances the anabolic pathway for 5-FU in combination treatment. Br. J. Cancer, 78 (Suppl. 2), 98 p. 12, 1998; Oncologist 1999;4(6):478-87. This may underpin the efficacy of 5-FU and oxaliplatin combination chemotherapy treatment in cancer. Moreover,
15 because 5-FU-based and platinum-based chemotherapy are known to be dependant on *TS* and *ERCC1* expression levels, respectively, it is particularly important to make an accurate determination of *ERCC1* expression and *TS* expression from patient derived tumor tissue samples to prognosticate a 5-FU-based and platinum-based chemotherapy.

20 Most patient derived pathological samples are routinely fixed and paraffin-embedded (FPE) to allow for histological analysis and subsequent archival storage. Thus, most biopsy tissue samples are not useful for analysis of gene expression because such studies require a high integrity of RNA so that an accurate measure of gene expression can be made. Currently, gene expression levels can be only
25 qualitatively monitored in such fixed and embedded samples by using

immunohistochemical staining to monitor protein expression levels.

Until now, quantitative gene expression studies including those of *ERCC1* and *TS* expression have been limited to reverse transcriptase polymerase chain reaction (RT-PCR) amplification of RNA from fresh or frozen tissue. U.S. Patent
5 No. 5,705,336 to Reed *et al.*, discloses a method of quantifying *ERCC1* mRNA from ovarian tumor tissue and determining whether that tissue will be sensitive to platinum-based chemotherapy. As in Leichman *et al.*, Reed *et al.*, quantify mRNA from frozen tumor biopsies.

The use of frozen tissue by health care professionals as described in
10 Leichman *et al.*, and Reed *et al.*, poses substantial inconveniences. Rapid biopsy delivery to avoid tissue and subsequent mRNA degradation is the primary concern when planning any RNA-based quantitative genetic marker assay. The health care professional performing the biopsy, must hastily deliver the tissue sample to a facility equipped to perform an RNA extraction protocol immediately upon tissue
15 sample receipt. If no such facility is available, the clinician must promptly freeze the sample in order to prevent mRNA degradation. In order for the diagnostic facility to perform a useful RNA extraction protocol prior to tissue and RNA degradation, the tissue sample must remain frozen until it reaches the diagnostic facility, however far away that may be. Maintaining frozen tissue integrity during
20 transport using specialized couriers equipped with liquid nitrogen and dry ice, comes only at a great expense.

Routine biopsies generally comprise a heterogeneous mix of stromal and tumorous tissue. Unlike with fresh or frozen tissue, FPE biopsy tissue samples are readily microdissected and separated into stromal and tumor tissue and therefore,
25 offer advantage over the use of fresh or frozen tissue. However, isolation of RNA

from fixed tissue, and especially fixed and paraffin embedded tissue, results in highly degraded RNA, which is generally not thought to be applicable to gene expression studies.

A number of techniques exist for the purification of RNA from biological samples, but none is reliable for isolation of RNA from FPE samples. For example, Chomczynski (U.S. Pat. No. 5,346,994) describes a method for purifying RNA from tissues based on a liquid phase separation using phenol and guanidine isothiocyanate. A biological sample is homogenized in an aqueous solution of phenol and guanidine isothiocyanate and the homogenate thereafter mixed with chloroform. Following centrifugation, the homogenate separates into an organic phase, an interphase and an aqueous phase. Proteins are sequestered in the organic phase, DNA in the interphase, and RNA in the aqueous phase. RNA can be precipitated from the aqueous phase. Unfortunately, this method is not applicable to fixed and paraffin-embedded (FPE) tissue samples.

Other known techniques for isolating RNA typically utilize either guanidine salts or phenol extraction, as described for example in Sambrook, J. *et al.*, (1989) at pp. 7.3-7.24, and in Ausubel, F. M. *et al.*, (1994) at pp. 4.0.3-4.4.7. Again, none of the known methods provides reproducible quantitative results in the isolation of RNA from paraffin-embedded tissue samples.

Techniques for the isolation of RNA from paraffin-embedded tissues are thus particularly needed for the study of gene expression in tumor tissues, since expression levels of certain receptors or enzymes can be used to determine the likelihood of success of a particular treatment.

Molecular predictive markers for resistance or sensitivity of oxaliplatin have

not yet been determined. There is a need for such markers to determine the likelihood of success of oxaliplatin/5-FU based therapies. We report here a significant inverse association for both the intratumoral mRNA expression of the excision repair gene *ERCC1* and intratumoral mRNA expression of the thymidylate synthase gene (*TS*) with clinical outcome in patients with tumors undergoing 5-FU/oxaliplatin combination-chemotherapy.

Accordingly, it is the object of the invention to provide a method of quantifying *ERCC1* and/or *TS* mRNA from tumor tissue in order to provide an early prognosis for proposed genotoxic cancer therapies. It is also the object of the invention to provide a method for assessing *ERCC1* and/or *TS* levels in tissues fixed and paraffin-embedded (FPE) and predicting the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin by examining the amount *ERCC1* and/or *TS* mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level.

SUMMARY OF THE INVENTION

In one aspect of the invention there is provided a method for assessing levels of expression of *ERCC1* mRNA obtained from fixed or fixed and paraffin-embedded (FPE) tumor cells.

5 In another aspect of the invention there is provided a method for assessing levels of expression of *TS* mRNA obtained from fixed or fixed and paraffin-embedded (FPE) tumor cells.

In another aspect of the invention there is provided a method of quantifying the amount of *ERCC1* mRNA expression relative to an internal control from a fixed and paraffin-embedded (FPE) tissue sample. This method includes isolation of total
10 mRNA from said sample and determining the quantity of *ERCC1* mRNA relative to the quantity of an internal control gene's mRNA.

In another aspect of the invention there is provided a method of quantifying the amount of *TS* mRNA expression relative to an internal control from a fixed and paraffin-embedded (FPE) tissue sample. This method includes isolation of total
15 mRNA from said sample and determining the quantity of *TS* mRNA relative to the quantity of an internal control gene's mRNA.

In an embodiment of this aspect of the invention, there are provided oligonucleotide primers having the sequence of ERCC1-504F (SEQ ID NO: 1) or
20 ERCC1-574R (SEQ ID NO:2) and sequences substantially identical thereto. The invention also provides for oligonucleotide primers having a sequence that hybridizes to SEQ ID NO: 1 or SEQ ID NO:2 or their complements under stringent conditions.

In another embodiment of this aspect of the invention, there are provided

oligonucleotide primers having the sequence of TS-763F (SEQ ID NO: 3) or TS-825R (SEQ ID NO: 4) and sequences substantially identical thereto. The invention also provides for oligonucleotide primers having a sequence that hybridizes to SEQ ID NO: 3 or SEQ ID NO:4 or their complements under stringent conditions.

5 In yet another aspect of the invention there is provided a method for determining a 5-FU and oxaliplatin-based chemotherapeutic regimen for a patient, comprising isolating RNA from a fixed and paraffin-embedded (FPE) tumor sample; determining a gene expression level of *ERCC1* in the sample; comparing the *ERCC1* gene expression levels in the sample with a predetermined threshold level for the
10 *ERCC1* gene; and determining a chemotherapeutic regimen based on results of the comparison of the *ERCC1* gene expression level with the predetermined threshold level.

 In yet another aspect of the invention there is provided a method for determining a 5-FU and oxaliplatin-based chemotherapeutic regimen for a patient,
15 comprising isolating RNA from a fixed and paraffin-embedded (FPE) tumor sample; determining a gene expression level of *TS* in the sample; comparing the *TS* gene expression levels in the sample with a predetermined threshold level for the *TS* gene; and determining a chemotherapeutic regimen based on results of the comparison of the *TS* gene expression level with the predetermined threshold level.

20 In yet another aspect of the invention there is provided a method for determining a 5-FU and oxaliplatin-based chemotherapeutic regimen for a patient, comprising isolating RNA from a fixed and paraffin-embedded (FPE) tumor sample; determining gene expression levels of *TS* and *ERCC1* in the sample; comparing the *TS* and *ERCC1* gene expression levels in the sample with a predetermined threshold

level for each of the *TS* and *ERCC1* genes; and determining a chemotherapeutic regimen based on results of the comparison of the *TS* and *ERCC1* gene expression levels with the predetermined threshold levels.

The invention further relates to a method of normalizing the uncorrected
5 gene expression (UGE) of *ERCC1* and *TS* relative to an internal control gene in a tissue sample analyzed using TaqMan® technology to known *ERCC1* and *TS* expression levels relative to an internal control from samples analyzed by pre-TaqMan® technology.

DESCRIPTION OF THE DRAWING

10 Figure 1 is a graph showing the estimated probability of survival and survival in months of colorectal adenocarcinoma tumor carrying patients with high (greater than about 7.5×10^{-3} times β -actin gene expression; n=7) and low (less than about 7.5×10^{-3} times β -actin gene expression; n=43) corrected *TS* expression levels receiving 5-FU and oxaliplatin therapeutic regimen.

15 Figure 2 is a graph showing the estimated probability of survival and survival in months of colorectal adenocarcinoma tumor carrying patients with high (greater than about 4.9×10^{-3} times β -actin gene expression; n=10) and low (less than about 4.9×10^{-3} times β -actin gene expression; n=40) corrected *ERCC1* expression levels receiving 5-FU and oxaliplatin therapeutic regimen.

20 Figure 3 is a graph showing the estimated probability of survival and survival in months of colorectal adenocarcinoma tumor carrying patients with high (*TS* expression greater than about 7.5×10^{-3} times β -actin gene expression and

ERCC1 greater than about 4.9×10^{-3} times β -actin gene expression; $n=14$) and low (*TS* expression less than about 7.5×10^{-3} times β -actin gene expression and *ERCC1* less than about 4.9×10^{-3} times β -actin gene expression; $n=36$) corrected *TS* and *ERCC1* expression levels receiving 5-FU and oxaliplatin therapeutic regimen.

5 Figure 4 is a table showing the survival of oxaliplatin/5-FU treated colorectal cancer patients relative to *ERCC1* and *TS* expression analyzed by univariate analysis.

Figure 5 is a table showing the survival of oxaliplatin/5-FU treated colorectal cancer patients relative to *ERCC1* and *TS* expression analyzed by stratified analysis.

10 Figure 6 is a graph showing the response of colorectal adenocarcinoma tumor carrying patients treated with a 5-FU and oxaliplatin chemotherapeutic regimen relative to. Patients were classified into those with progressive disease (PD), partial response (PR), and stable disease (SD). Patients with low levels of both *TS* and *ERCC1* expression had the best response.

15 Figure 7 is a chart illustrating how to calculate *ERCC1* expression relative to an internal control gene. The chart contains data obtained with two test samples, (unknowns 1 and 2), and illustrates how to determine the uncorrected gene expression data (UGE). The chart also illustrates how to normalize UGE generated by the TaqMan® instrument with known relative *ERCC1* values determined by pre-
20 TaqMan® technology. This is accomplished by multiplying UGE to a correction factor K_{ERCC1} . The internal control gene in the figure is β -actin and the calibrator RNA is Human Liver Total RNA (Stratagene, Cat. #735017).

Figure 8 is a chart illustrating how to calculate *TS* expression relative to an

internal control gene. The chart contains data obtained with two test samples, (unknowns 1 and 2), and illustrates how to determine the uncorrected gene expression data (UGE). The chart also illustrates how to normalize UGE generated by the TaqMan® instrument with previously published *TS* values. This is
5 accomplished by multiplying UGE to a correction factor K_{TS} . The internal control gene in the figure is β -actin and the calibrator RNA is Universal PE RNA; Cat #4307281, lot # 3617812014 from Applied Biosystems.

Figure 9 is a table showing colorectal cancer patients' tumors response to oxaliplatin/5-FU treatment relative *TS* expression.

DETAILED DESCRIPTION OF THE INVENTION

The present invention resides in part in the finding that the amount of *TS* and *ERCC1* mRNA is correlated with resistance to 5-FU and oxaliplatin agents, respectively. Tumors expressing high levels of *TS* and/or *ERCC1* mRNA are
5 considered likely to be resistant to platinum-based chemotherapy. Conversely, those tumors expressing low amounts of *TS* and *ERCC1* mRNA are likely to be sensitive to platinum-based chemotherapy. A patient's tumor *TS* and *ERCC1* mRNA expression status is judged by comparing it to a predetermined threshold expression level.

10 The invention provides a method of quantifying the amount of *TS* and/or *ERCC1* mRNA expression in fixed or fixed and paraffin-embedded (FPE) tissue relative to gene expression of an internal control. The present inventors have developed oligonucleotide primers that allow accurate assessment of *TS* and *ERCC1* gene expression in tissues that have been fixed or fixed and embedded. The
15 invention oligonucleotide primers, ERCC1-504F (SEQ ID NO: 1), ERCC1-574R (SEQ ID NO: 2), or oligonucleotide primers substantially identical thereto, preferably are used together with RNA extracted from fixed and paraffin embedded (FPE) tumor samples. The invention also provides oligonucleotide primers, TS-763F (SEQ ID NO: 3), TS-825R (SEQ ID NO: 4), or oligonucleotide primers
20 substantially identical thereto, preferably are used together with RNA extracted from fixed and paraffin embedded (FPE) tumor samples. This measurement of *TS* and/or *ERCC1* gene expression may then be used for prognosis of platinum-based chemotherapy

This embodiment of the invention involves first, a method for reliable

extraction of RNA from an FPE sample and second, determination of the content of *ERCC1* mRNA in the sample by using a pair of oligonucleotide primers, preferably oligonucleotide primer pair ERCC1-504F (SEQ ID NO: 1) and ERCC1-574R (SEQ ID NO: 2), or oligonucleotides substantially identical thereto, for carrying out
5 reverse transcriptase polymerase chain reaction.

"Substantially identical" in the nucleic acid context as used herein, means hybridization to a target under stringent conditions, and also that the nucleic acid segments, or their complementary strands, when compared, are the same when properly aligned, with the appropriate nucleotide insertions and deletions, in at least
10 about 60% of the nucleotides, typically, at least about 70%, more typically, at least about 80%, usually, at least about 90%, and more usually, at least, about 95-98% of the nucleotides. Selective hybridization exists when the hybridization is more selective than total lack of specificity. See, Kanehisa, *Nucleic Acids Res.*, 12:203-213 (1984).

15 This embodiment of the invention further involves first determination of the content of *TS* mRNA in the sample by using a pair of oligonucleotide primers, preferably oligonucleotide primer pair TS-763F (SEQ ID NO: 3) and TS-825R (SEQ ID NO: 4), or oligonucleotides substantially identical thereto, for carrying out reverse transcriptase polymerase chain reaction. RNA is extracted from the FPE
20 cells by any of the methods for mRNA isolation from such samples as described in US Patent Application No. 09/469,338, filed December 20, 1999, and is hereby incorporated by reference in its entirety.

The present method can be applied to any type of tissue from a patient. For examination of resistance of tumor tissue, it is preferable to examine the tumor

tissue. In a preferred embodiment, a portion of normal tissue from the patient from which the tumor is obtained, is also examined. Patients whose normal tissues are expected to be resistant to platinum-based chemotherapeutic compounds, i.e., show a high level of *TS* and/or *ERCC1* gene expression, but those whose tumors are
5 expected to be sensitive to such compounds, i.e. show a low level of *TS* and/or *ERCC1* gene expression, may then be treated with higher amounts of the chemotherapeutic composition.

The methods of the present invention can be applied over a wide range of tumor types. This allows for the preparation of individual "tumor expression
10 profiles" whereby expression levels of *TS* and/or *ERCC1* are determined in individual patient samples and response to various chemotherapeutics is predicted. Preferably, the methods of the invention are applied to solid tumors, most preferably colorectal adenocarcinoma tumors.

A "predetermined threshold level", as defined herein relating to *ERCC1*
15 expression, is a level of *ERCC1* expression above which it has been found that tumors are likely to be resistant to a 5-FU and/or oxaliplatin-based chemotherapeutic regimen. Expression levels below this threshold level are likely to be found in tumors sensitive to 5-FU and/or oxaliplatin-based chemotherapeutic regimen. The range of relative expression of *ERCC1*, expressed as a ratio of *ERCC1* : β -actin,
20 among tumors responding to a platinum-based chemotherapeutic regimen is less than about 4.9×10^{-3} . Tumors that do not respond to a platinum-based chemotherapeutic regimen have relative expression of *ERCC1* : β -actin ratio above about 4.9×10^{-3} .

A "predetermined threshold level", as defined herein relating to *TS*, is a level of *TS* expression above which it has been found that tumors are likely to be resistant to a 5-FU and 5-FU and oxaliplatin-based chemotherapeutic regimen. Expression levels below this threshold level are likely to be found in tumors sensitive to 5-FU or
5 5-FU and oxaliplatin-based chemotherapeutic regimen. The range of relative expression of *TS*, expressed as a ratio of *TS* : β -actin, among tumors responding to a 5-FU or 5-FU and oxaliplatin-based chemotherapeutic regimen is less than about 7.5×10^{-3} . Tumors that do not respond to a 5-FU or 5-FU and oxaliplatin-based chemotherapeutic regimen have relative expression of *TS* : β -actin
10 ratio above about 7.5×10^{-3} .

In performing the method of the present invention either *ERCC1* expression levels or *TS* expression levels are assayed in patient tumor samples to prognosticate the efficacy of a 5-FU and oxaliplatin-based chemotherapeutic regimen. Moreover, in the method of the present invention *TS* expression levels are assayed in patient
15 tumor samples to prognosticate the efficacy of a 5-FU based chemotherapeutic regimen. Additionally, in the method of the present invention *ERCC1* expression levels are assayed in patient tumor samples to prognosticate the efficacy of a oxaliplatin based chemotherapeutic regimen. Alternatively, both *ERCC1* expression levels and *TS* expression levels are assayed in patient tumor samples to
20 prognosticate the efficacy of a combined 5-FU and oxaliplatin-based chemotherapeutic regimen.

In performing the method of this embodiment of the present invention, tumor cells are preferably isolated from the patient. Solid or lymphoid tumors or portions

thereof are surgically resected from the patient or obtained by routine biopsy. RNA isolated from frozen or fresh samples is extracted from the cells by any of the methods typical in the art, for example, Sambrook, Fischer and Maniatis, Molecular Cloning, a laboratory manual, (2nd ed.), Cold Spring Harbor Laboratory Press, New York, (1989). Preferably, care is taken to avoid degradation of the RNA during the extraction process.

However, tissue obtained from the patient after biopsy is often fixed, usually by formalin (formaldehyde) or glutaraldehyde, for example, or by alcohol immersion. Fixed biological samples are often dehydrated and embedded in paraffin or other solid supports known to those of skill in the art. See Plenat *et al.*, Ann Pathol 2001 Jan;21(1):29-47. Non-embedded, fixed tissue as well as fixed and embedded tissue may also be used in the present methods. Solid supports for embedding fixed tissue are envisioned to be removable with organic solvents for example, allowing for subsequent rehydration of preserved tissue.

RNA is extracted from the FPE cells by any of the methods as described in US Patent Application No. 09/469,338, filed December 20, 1999, which is hereby incorporated by reference in its entirety. Fixed and paraffin-embedded (FPE) tissue samples as described herein refers to storable or archival tissue samples. RNA may be isolated from an archival pathological sample or biopsy sample which is first deparaffinized. An exemplary deparaffinization method involves washing the paraffinized sample with an organic solvent, such as xylene, for example. Deparaffinized samples can be rehydrated with an aqueous solution of a lower alcohol. Suitable lower alcohols, for example include, methanol, ethanol, propanols, and butanols. Deparaffinized samples may be rehydrated with successive washes

with lower alcoholic solutions of decreasing concentration, for example.

Alternatively, the sample is simultaneously deparaffinized and rehydrated. RNA is then extracted from the sample.

For RNA extraction, the fixed or fixed and deparaffinized samples can be
5 homogenized using mechanical, sonic or other means of homogenization.

Rehydrated samples may be homogenized in a solution comprising a chaotropic agent, such as guanidinium thiocyanate (also sold as guanidinium isothiocyanate).

Homogenized samples are heated to a temperature in the range of about 50 to about 100 °C in a chaotropic solution, which contains an effective amount of a chaotropic
10 agent, such as a guanidinium compound. A preferred chaotropic agent is guanidinium thiocyanate.

An "effective concentration of chaotropic agent" is chosen such that at an RNA is purified from a paraffin-embedded sample in an amount of greater than about 10-fold that isolated in the absence of a chaotropic agent. Chaotropic agents
15 include, for example: guanidinium compounds, urea, formamide, potassium iodide, potassium thiocyanate and similar compounds. The preferred chaotropic agent for the methods of the invention is a guanidinium compound, such as guanidinium isothiocyanate (also sold as guanidinium thiocyanate) and guanidinium hydrochloride. Many anionic counterions are useful, and one of skill in the art can
20 prepare many guanidinium salts with such appropriate anions. The effective concentration of guanidinium solution used in the invention generally has a concentration in the range of about 1 to about 5M with a preferred value of about 4M. If RNA is already in solution, the guanidinium solution may be of higher concentration such that the final concentration achieved in the sample is in the range

of about 1 to about 5M. The guanidinium solution also is preferably buffered to a pH of about 3 to about 6, more preferably about 4, with a suitable biochemical buffer such as Tris-Cl. The chaotropic solution may also contain reducing agents, such as dithiothreitol (DTT) and β -mercaptoethanol (BME). The chaotropic solution
5 may also contain RNase inhibitors.

RNA is then recovered from the chaotropic solution by, for example, phenol chloroform extraction, ion exchange chromatography or size-exclusion chromatography. RNA may then be further purified using the techniques of extraction, electrophoresis, chromatography, precipitation or other suitable
10 techniques.

The quantification of *TS* or *ERCC1* mRNA from purified total mRNA from fresh, frozen or fixed is preferably carried out using reverse-transcriptase polymerase chain reaction (RT-PCR) methods common in the art, for example. Other methods of quantifying of *TS* or *ERCC1* mRNA include for example, the use of molecular
15 beacons and other labeled probes useful in multiplex PCR. Additionally, the present invention envisages the quantification of *TS* and/or *ERCC1* mRNA via use of a PCR-free systems employing, for example fluorescent labeled probes similar to those of the Invader® Assay (Third Wave Technologies, Inc.). Most preferably, quantification of *TS* and/or *ERCC1* cDNA and an internal control or house keeping
20 gene (e.g. β -actin) is done using a fluorescence based real-time detection method (ABI PRISM 7700 or 7900 Sequence Detection System [TaqMan®], Applied Biosystems, Foster City, CA.) or similar system as described by Heid *et al.*, (Genome Res 1996;6:986-994) and Gibson *et al.* (Genome Res 1996;6:995-1001).

The output of the ABI 7700 (TaqMan® Instrument) is expressed in Ct's or "cycle thresholds". With the TaqMan® system, a highly expressed gene having a higher number of target molecules in a sample generates a signal with fewer PCR cycles (lower Ct) than a gene of lower relative expression with fewer target molecules
5 (higher Ct).

As used herein, a "house keeping" gene or "internal control" is meant to include any constitutively or globally expressed gene whose presence enables an assessment of *TS* and/or *ERCC1* mRNA levels. Such an assessment comprises a determination of the overall constitutive level of gene transcription and a control for
10 variations in RNA recovery. "House-keeping" genes or "internal controls" can include, but are not limited to the cyclophilin gene, β -actin gene, the transferrin receptor gene, GAPDH gene, and the like. Most preferably, the internal control gene is β -actin gene as described by Eads *et al.*, Cancer Research 1999; 59:2302-2306.

A control for variations in RNA recovery requires the use of "calibrator
15 RNA." The "calibrator RNA" is intended to be any available source of accurately pre-quantified control RNA. Preferably, Human Liver Total RNA (Stratagene, Cat. #735017) is used in quantifying *ERCC1* and Universal PE RNA; Cat #4307281, lot # 3617812014 from Applied Biosystems is used in quantifying *TS*.

"Uncorrected Gene Expression (UGE)" as used herein refers to the numeric
20 output of *TS* and/or *ERCC1* expression relative to an internal control gene generated by the TaqMan® instrument. The equation used to determine UGE is shown in Examples 3 and 4, and illustrated with sample calculations in Figures 7 and 8.

A further aspect of this invention provides a method to normalize

uncorrected gene expression (UGE) values acquired from the TaqMan® instrument with "known relative gene expression" values derived from non-TaqMan® technology. Preferably, TaqMan® derived *TS* and/or *ERCC1* UGE values from a tissue sample are normalized to samples with known non-TaqMan® derived relative

5 *TS* and/or *ERCC1* : β -actin expression values.

"Corrected Relative *ERCC1* Expression" as used herein refers to normalized *ERCC1* expression whereby UGE is multiplied with a *ERCC1* specific correction factor (K_{ERCC1}), resulting in a value that can be compared to a known range of *ERCC1* expression levels relative to an internal control gene. Example 3 and Figure

10 7 illustrate these calculations in detail. These numerical values allow the determination of whether or not the "Corrected Relative *ERCC1* Expression" of a particular sample falls above or below the "predetermined threshold" level. The predetermined threshold level of Corrected Relative *ERCC1* Expression to β -actin level is about 4.9×10^{-3} . K_{ERCC1} specific for *ERCC1*, the internal control β -actin and

15 calibrator Human Liver Total RNA (Stratagene, Cat. #735017), is 1.54×10^{-3} .

"Known relative gene expression" values are derived from previously analyzed tissue samples and are based on the ratio of the RT-PCR signal of a target gene to a constitutively expressed internal control gene (e.g. β -Actin, GAPDH, etc.). Preferably such tissue samples are formalin fixed and paraffin-embedded (FPE)

20 samples and RNA is extracted from them according to the protocol described in Example 1 and in US Patent Application No. 09/469,338, filed December 20, 1999, which is hereby incorporated by reference in its entirety. To quantify gene expression relative to an internal control standard quantitative RT-PCR technology

known in the art is used. Pre-TaqMan® technology PCR reactions are run for a fixed number of cycles (i.e., 30) and endpoint values are reported for each sample. These values are then reported as a ratio of *ERCC1* expression to β -actin expression. See U.S. Patent No. 5,705,336 to Reed et al.

5 K_{ERCC1} may be determined for an internal control gene other than β -actin and/or a calibrator RNA different than Human Liver Total RNA (Stratagene, Cat. #735017). To do so, one must calibrate both the internal control gene and the calibrator RNA to tissue samples for which *ERCC1* expression levels relative to that particular internal control gene have already been determined (i.e., "known relative
10 gene expression"). Preferably such tissue samples are formalin fixed and paraffin-embedded (FPE) samples and RNA is extracted from them according to the protocol described in Example 1 and in US Patent Application No. 09/469,338, filed December 20, 1999, which is hereby incorporated by reference in its entirety. Such a determination can be made using standard pre-TaqMan®, quantitative RT-PCR
15 techniques well known in the art. Upon such a determination, such samples have "known relative gene expression" levels of *ERCC1* useful in the determining a new K_{ERCC1} specific for the new internal control and/or calibrator RNA as described in Example 3.

"Corrected Relative *TS* Expression" as used herein refers to normalized *TS*
20 expression whereby UGE is multiplied with a *TS* specific correction factor (K_{TS}), resulting in a value that can be compared to a known range of *TS* expression levels relative to an internal control gene. Example 4 and Figure 8 illustrate these calculations in detail. These numerical values allow the determination of whether

the "Corrected Relative *TS* Expression" of a particular sample falls above or below the "predetermined threshold" level. The predetermined threshold level of Corrected Relative *TS* Expression to β -actin level is about 7.5×10^{-3} . K_{TS} specific for *TS*, the internal control β -actin and calibrator Universal PE RNA; Cat #4307281, lot #

5 3617812014 from Applied Biosystems, is 12.6×10^{-3} .

K_{TS} may be determined for an internal control gene other than β -actin and/or a calibrator RNA different than Universal PE RNA; Cat #4307281, lot # 3617812014 from Applied Biosystems. To do so, one must calibrate both the internal control gene and the calibrator RNA to tissue samples for which *TS*

10 expression levels relative to that particular internal control gene have already been determined (i.e., "known relative gene expression" or "previously published"). Preferably such tissue samples are formalin fixed and paraffin-embedded (FPE) samples and RNA is extracted from them according to the protocol described in Example 1 and in US Patent Application No. 09/469,338, filed December 20, 1999,

15 which is hereby incorporated by reference in its entirety. Such a determination can be made using standard pre-TaqMan®, quantitative RT-PCR techniques well known in the art. Upon such a determination, such samples have "known relative gene expression" levels of *TS* useful in the determining a new K_{TS} specific for the new internal control and/or calibrator RNA as described in Example 4.

20 "Previously published" relative gene expression results are based on the ratio of the RT-PCR signal of a target gene to a constitutively expressed gene (β -Actin). In pre-TaqMan® technology studies, PCR reactions were run for a fixed number of cycles (i.e., 30) and endpoint values were reported for each sample. These values

were then reported as a ratio of *ERCC1* or *TS* expression to β -actin expression.

Salonga, *et al.*, Clinical Cancer Research, 6:1322-1327, 2000, incorporated herein by reference in its entirety.

The methods of the invention are applicable to a wide range of tissue and
5 tumor types and so can be used for assessment of clinical treatment of a patient and
as a diagnostic or prognostic tool for a range of cancers including breast, head and
neck, lung, esophageal, colorectal, and others. In a preferred embodiment, the
present methods are applied to prognosis of colorectal adenocarcinoma.

Pre-chemotherapy treatment tumor biopsies are usually available only as
10 fixed paraffin embedded (FPE) tissues, generally containing only a very small
amount of heterogeneous tissue. Such FPE samples are readily amenable to
microdissection, so that *TS* and/or *ERCC1* gene expression may be determined in
tumor tissue uncontaminated with stromal tissue. Additionally, comparisons can be
made between stromal and tumor tissue within a biopsy tissue sample, since such
15 samples often contain both types of tissues.

Generally, any oligonucleotide pairs that flank a region of *ERCC1* gene, as
shown in SEQ ID NO: 10, may be used to carry out the methods of the invention.
Primers hybridizing under stringent conditions to a region of the *ERCC1* gene for
use in the present invention will amplify a product between 20-1000 base pairs,
20 preferably 50-100 base pairs, most preferably less than 100 base pairs.

The invention provides specific oligonucleotide primer pairs and
oligonucleotide primers substantially identical thereto, that allow particularly
accurate assessment of *ERCC1* expression using FPE tissues. Preferable are

oligonucleotide primers, ERCC1-504F (SEQ ID NO: 1) and ERCC1 (SEQ ID NO: 2), (also referred to herein as the oligonucleotide primer pair ERCC1) and oligonucleotide primers substantially identical thereto. The oligonucleotide primers ERCC1-504F (SEQ ID NO: 1) and ERCC1, (SEQ ID NO: 2) have been
5 shown to be particularly effective for measuring *ERCC1* mRNA levels using RNA extracted from the FPE cells by any of the methods for mRNA isolation, for example as described Example 1.

Furthermore, any oligonucleotide pairs that flank a region of *TS* gene, as shown in SEQ ID NO: 11, may be used to carry out the methods of the invention.
10 Primers hybridizing under stringent conditions to a region of the *TS* gene for use in the present invention will amplify a product between 20-1000 base pairs, preferably 50-100 base pairs, most preferably less than 100 base pairs.

The invention provides specific oligonucleotide primers pairs and oligonucleotide primers substantially identical thereto, that allow particularly
15 accurate assessment of *TS* expression in FPE tissues. Preferable are oligonucleotide primers, TS-763F (SEQ ID NO: 3) and TS (SEQ ID NO: 4), (also referred to herein as the oligonucleotide primer pair TS) and oligonucleotide primers substantially identical thereto. The oligonucleotide primers TS-763F (SEQ ID NO: 3) and TS, (SEQ ID NO: 4) have been shown to be particularly effective for measuring *TS*
20 mRNA levels using RNA extracted from the FPE cells by any of the methods for mRNA isolation, for example as described Example 1.

This invention includes substantially identical oligonucleotides that hybridize under stringent conditions (as defined herein) to all or a portion of the oligonucleotide primer sequence of ERCC1-504F (SEQ ID NO: 1), its complement

or ERCC1-574R (SEQ ID NO: 2), or its complement or oligonucleotide primer sequence of TS-763F (SEQ ID NO: 3), its complement or TS-825R (SEQ ID NO: 4), or its complement.

Under stringent hybridization conditions, only highly complementary, i.e.,
5 substantially similar nucleic acid sequences as defined herein hybridize. Preferably, such conditions prevent hybridization of nucleic acids having 4 or more mismatches out of 20 contiguous nucleotides, more preferably 2 or more mismatches out of 20 contiguous nucleotides, most preferably one or more mismatch out of 20 contiguous nucleotides.

10 The hybridizing portion of the nucleic acids is typically at least about 10 (e.g., 15) nucleotides in length. The hybridizing portion of the hybridizing nucleic acid is at least about 80%, preferably at least about 95%, or most preferably about at least 98%, identical to the sequence of a portion or all of oligonucleotide primer ERCC1-504F (SEQ ID NO: 1), its complement or ERCC1-574R (SEQ ID NO: 2),
15 or its complement or oligonucleotide primer TS-763F (SEQ ID NO: 3), its complement or TS-825R (SEQ ID NO: 4), or its complement.

Hybridization of the oligonucleotide primer to a nucleic acid sample under stringent conditions is defined below. Nucleic acid duplex or hybrid stability is expressed as a melting temperature (T_m), which is the temperature at which the probe
20 dissociates from the target DNA. This melting temperature is used to define the required stringency conditions. If sequences are to be identified that are substantially identical to the probe, rather than identical, then it is useful to first establish the lowest temperature at which only homologous hybridization occurs with a particular concentration of salt (e.g. SSC or SSPE). Then assuming that 1%

mismatching results in a 1°C decrease in T_m , the temperature of the final wash in the hybridization reaction is reduced accordingly (for example, if sequences having >95% identity with the probe are sought, the final wash temperature is decreased by 5°C). In practice, the change in T_m can be between 0.5°C and 1.5°C per 1%

5 mismatch.

Stringent conditions involve hybridizing at 68°C in 5x SSC/5x Denhart's solution/1.0% SDS, and washing in 0.2x SSC/0.1% SDS at room temperature.

Moderately stringent conditions include washing in 3x SSC at 42°C. The parameters of salt concentration and temperature be varied to achieve optimal level
10 of identity between the primer and the target nucleic acid. Additional guidance regarding such conditions is readily available in the art, for example, Sambrook, Fischer and Maniatis, Molecular Cloning, a laboratory manual, (2nd ed.), Cold Spring Harbor Laboratory Press, New York, (1989) and F. M. Ausubel et al eds., Current Protocols in Molecular Biology, John Wiley and Sons (1994).

15 Oligonucleotide primers disclosed herein are capable of allowing accurate assessment of *TS* and/or *ERCC1* gene expression in a fixed or fixed and paraffin embedded tissue, as well as frozen or fresh tissue. This is despite the fact that RNA derived from FPE samples is more fragmented relative to that of fresh or frozen tissue. Thus, the methods of the invention are suitable for use in assaying *TS* and/or
20 *ERCC1* gene expression levels in FPE tissue where previously there existed no way to assay *TS* and/or *ERCC1* gene expression using fixed tissues.

Genotoxic agents that can be used in combination to a 5-FU and oxaliplatin based chemotherapy are those that form persistent genomic lesions and are preferred for use as chemotherapeutic agents in the clinical management of cancer. The rate of

cellular repair of genotoxin-induced DNA damage, as well as the rate of cell growth via the cell division cycle, affects the outcome of genotoxin therapy. Unrepaired lesions in a cell's genome can impede DNA replication, impair the replication fidelity of newly synthesized DNA or hinder the expression of genes needed for cell survival. Thus, one determinant of a genotoxic agent's cytotoxicity (propensity for contributing to cell death) is the resistance of genomic lesions formed therefrom to cellular repair. Genotoxic agents that form persistent genomic lesions, e.g., lesions that remain in the genome at least until the cell commits to the cell cycle, generally are more effective cytotoxins than agents that form transient, easily repaired genomic lesions.

The genotoxin, Oxaliplatin, i.e., cis-oxalato(trans-1-1,2-cyclohexanediamine) platinum (II) is described in U.S. Pat. No. 4,169,846. Related patents include: U.S. Pat. No. 5,290,961; U.S. Pat. No. 5,298,642; U.S. Pat. No. 5,338,874; U.S. Pat. No. 5,420,319 and PCT/IB/00614. Oxaliplatin belongs to the class of platinum(II)-trans-1,2-diaminocyclohexane complexes which are currently in full development. Said complexes, or "dach" complexes are being clinically tested and are especially efficient against melanomae and tumors of the ovaries, uterus, stomach and intestine, etc. Other compounds that can be used to supplement 5-FU and oxaliplatin based chemotherapies can also include members analogs of oxaliplatin such as "dach" complexes and those that form covalent DNA adducts. In a preferred embodiment, the supplemental platinum compound used the present invention is oxaliplatin.

Tumors currently manageable by platinum coordination compounds include testicular, endometrial, cervical, gastric, squamous cell, adrenocortical and small cell lung carcinomas, along with medulloblastomas and neuroblastomas.

The invention being thus described, practice of the invention is illustrated by the experimental examples provided below. The skilled practitioner will realize that the materials and methods used in the illustrative examples can be modified in various ways. Such modifications are considered to fall within the scope of the present invention.

EXAMPLES

EXAMPLE 1

RNA Isolation from FPE Tissue

10 RNA is extracted from paraffin-embedded tissue by the following general procedure.

A. Deparaffinization and hydration of sections:

(1) A portion of an approximately 10 μ M section is placed in a 1.5 mL plastic centrifuge tube.

15 (2) 600 μ L of xylene are added and the mixture is shaken vigorously for about 10 minutes at room temperature (roughly 20 to 25 °C).

(3) The sample is centrifuged for about 7 minutes at room temperature at the maximum speed of the bench top centrifuge (about 10-20,000 x g).

(4) Steps 2 and 3 are repeated until the majority of paraffin has been dissolved. Two or more times are normally required depending on the amount of paraffin included in the original sample portion.

(5) The xylene solution is removed by vigorously shaking with a lower alcohol, preferably with 100% ethanol (about 600 μ L) for about 3 minutes.

(6) The tube is centrifuged for about 7 minutes as in step (3). The supernatant is decanted and discarded. The pellet becomes white.

(7) Steps 5 and 6 are repeated with successively more dilute ethanol solutions: first with about 95% ethanol, then with about 80% and finally with
5 about 70% ethanol.

(8) The sample is centrifuged for 7 minutes at room temperature as in step (3). The supernatant is discarded and the pellet is allowed to dry at room temperature for about 5 minutes.

B. RNA Isolation with Phenol-Chloroform

10 (1) 400 μ L guanidine isothiocyanate solution including 0.5% sarcosine and 8 μ L dithiothreitol is added.

(2) The sample is then homogenized with a tissue homogenizer (Ultra-Turrax, IKA-Works, Inc., Wilmington, NC) for about 2 to 3 minutes while gradually increasing the speed from low speed (speed 1) to high speed (speed 5).

15 (3) The sample is then heated at about 95 °C for about 5-20 minutes. It is preferable to pierce the cap of the tube containing the sample with a fine gauge needle before heating to 95 °C. Alternatively, the cap may be affixed with a plastic clamp or with laboratory film.

(4) The sample is then extracted with 50 μ L 2M sodium acetate at pH 4.0
20 and 600 μ L of phenol/chloroform/isoamyl alcohol (10:1.93:0.036), prepared fresh by mixing 18 mL phenol with 3.6 mL of a 1:49 isoamyl alcohol:chloroform solution. The solution is shaken vigorously for about 10 seconds then cooled on ice for about 15 minutes.

(5) The solution is centrifuged for about 7 minutes at maximum speed. The

upper (aqueous) phase is transferred to a new tube.

(6) The RNA is precipitated with about 10 μ L glycogen and with 400 μ L isopropanol for 30 minutes at -20 °C.

(7) The RNA is pelleted by centrifugation for about 7 minutes in a benchtop
5 centrifuge at maximum speed; the supernatant is decanted and discarded; and the pellet washed with approximately 500 μ L of about 70 to 75% ethanol.

(8) The sample is centrifuged again for 7 minutes at maximum speed. The supernatant is decanted and the pellet air dried. The pellet is then dissolved in an appropriate buffer for further experiments (e.g., 50 μ L 5mM Tris chloride, pH 8.0).

10 EXAMPLE 2

mRNA Reverse Transcription and PCR

Reverse Transcription: RNA was isolated from microdissected or non-microdissected formalin fixed paraffin embedded (FPE) tissue as illustrated in Example 1 and as previously described in U.S. Application No. 09/469,338 filed
15 December 20, 1999, which is hereby incorporated by reference in its entirety. After precipitation with ethanol and centrifugation, the RNA pellet was dissolved in 50 μ L of 5 mM Tris/Cl at pH 8.0. M-MLV Reverse Transcriptase will extend an oligonucleotide primer hybridized to a single-stranded RNA or DNA template in the presence of deoxynucleotides, producing a complementary strand. The resulting
20 RNA was reverse transcribed with random hexamers and M-MLV Reverse Transcriptase from Life Technologies. The reverse transcription was accomplished by mixing 25 μ L of the RNA solution with 25.5 μ L of "reverse transcription mix"

(see below). The reaction was placed in a thermocycler for 8 min at 26/ C (for binding the random hexamers to RNA), 45 min at 42/ C (for the M-MLV reverse transcription enzymatic reaction) and 5 min at 95/ C (for heat inactivation of DNase).

- 5 "Reverse transcription mix" consists of 10 ul 5X buffer (250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl₂), 0.5 ul random hexamers (50 O.D. dissolved in 550 ul of 10 mM Tris-HCl pH 7.5) 5 ul 10 mM dNTPs (dATP, dGTP, dCTP and dTTP), 5 ul 0.1 M DTT, 1.25 ul BSA (3mg/ml in 10 mM Tris-HCL, pH 7.5), 1.25 ul RNA Guard 24,800U/ml (RNAse inhibitor) (Porcine #27-0816, Amersham
10 Pharmacia) and 2.5 ul MMLV 200U/ul (Life Tech Cat #28025-02).

Final concentrations of reaction components are: 50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl₂, 1.0 mM dNTP, 1.0 mM DTT, 0.00375. mg/ml BSA, 0.62 U/ul RNA Guard and 10 U/ ul MMLV.

PCR Quantification of mRNA expression. Quantification of *ERCC1*

- 15 cDNA and an internal control or house keeping gene (e.g., β -actin) cDNA was done using a fluorescence based real-time detection method (ABI PRISM 7700 or 7900 Sequence Detection System [TaqMan®], Applied Biosystems, Foster City, CA.) as described by Heid *et al.*, (Genome Res 1996;6:986-994); Gibson *et al.*, (Genome Res 1996;6:995-1001). In brief, this method uses a dual labelled fluorogenic
20 TaqMan® oligonucleotide probe, (ERCC1-530Tc (SEQ ID NO: 5), T_m = 70° C; TS-781 (SEQ ID NO: 6), β -actin-611 (SEQ ID NO: 7)) that anneals specifically within the forward and reverse primers. Laser stimulation within the capped wells containing the reaction mixture causes emission of a 3'quencher dye (TAMRA) until

the probe is cleaved by the 5' to 3' nuclease activity of the DNA polymerase during PCR extension, causing release of a 5' reporter dye (6FAM). Production of an amplicon thus causes emission of a fluorescent signal that is detected by the TaqMan®'s CCD (charge-coupled device) detection camera, and the amount of

5 signal produced at a threshold cycle within the purely exponential phase of the PCR reaction reflects the starting copy number of the sequence of interest. Comparison of the starting copy number of the sequence of interest with the starting copy number of the internal control gene provides a relative gene expression level. TaqMan® analyses yield levels that are expressed as ratios between two absolute

10 measurements (gene of interest/internal control gene).

The PCR reaction mixture consisted 0.5 µl of the reverse transcription reaction containing the cDNA prepared as described above 600 nM of each oligonucleotide primers ERCC1-504F (SEQ ID NO:1, $T_m = 59^\circ \text{C}$) and ERCC1-574R (SEQ ID NO: 2, $T_m = 58^\circ \text{C}$) or oligonucleotide primers TS-763F (SEQ ID

15 NO:3) and TS-825R (SEQ ID NO:4) 200 nM TaqMan® probe (SEQ ID NO:5 or SEQ ID NO: 6), 5 U AmpliTaq Gold Polymerase, 200 µM each dATP, dCTP, dGTP, 400 µM dTTP, 5.5 mM MgCl_2 , and 1 x Taqman Buffer A containing a reference dye, to a final volume of less than or equal to 25 µl (all reagents Applied Biosystems, Foster City, CA). Cycling conditions were, 95 °C for 10 min, followed

20 by 45 cycles at 95 °C for 15s and 60 °C for 1 min. Oligonucleotides used to quantify internal control gene β -Actin were β -Actin-592F (SEQ ID NO: 8) and β -Actin-651R (SEQ ID NO: 9).

EXAMPLE 3*Determining the Uncorrected Gene Expression (UGE) for ERCC1*

Two pairs of parallel reactions are carried out. The "test" reactions and the "calibration" reactions. Figure 7. The *ERCC1* amplification reaction and the β -actin internal control amplification reaction are the test reactions. Separate *ERCC1* and β -actin amplification reactions are performed on the calibrator RNA template and are referred to as the calibration reactions. The TaqMan® instrument will yield four different cycle threshold (Ct) values: Ct_{ERCC1} and $Ct_{\beta-actin}$ from the test reactions and Ct_{ERCC1} and $Ct_{\beta-actin}$ from the calibration reactions. The differences in Ct values for the two reactions are determined according to the following equation:

$$\begin{aligned}\Delta Ct_{test} &= Ct_{ERCC1} - Ct_{\beta-actin} && \text{(From the "test" reaction)} \\ \Delta Ct_{calibrator} &= Ct_{ERCC1} - Ct_{\beta-actin} && \text{(From the "calibration" reaction)}\end{aligned}$$

Next the step involves raising the number 2 to the negative ΔCt , according to the following equations.

$$\begin{aligned}2^{-\Delta Ct_{test}} &&& \text{(From the "test" reaction)} \\ 2^{-\Delta Ct_{calibrator}} &&& \text{(From the "calibration" reaction)}\end{aligned}$$

In order to then obtain an uncorrected gene expression for *ERCC1* from the TaqMan® instrument the following calculation is carried out:

20
$$\text{Uncorrected gene expression (UGE) for } ERCC1 = 2^{-\Delta Ct_{test}} / 2^{-\Delta Ct_{calibrator}}$$

Normalizing UGE with known relative ERCC1 expression levels

The normalization calculation entails a multiplication of the UGE with a correction factor (K_{ERCC1}) specific to *ERCC1* and a particular calibrator RNA. A

correction factor K_{ERCC1} can also be determined for any internal control gene and any accurately pre-quantified calibrator RNA. Preferably, the internal control gene β -actin and the accurately pre-quantified calibrator RNA, Human Liver Total RNA (Stratagene, Cat. #735017), are used. Given these reagents correction factor K_{ERCC1} equals 1.54×10^{-3} .

Normalization is accomplished using a modification of the ΔC_t method described by Applied Biosystems, the TaqMan® manufacturer, in User Bulletin #2 and described above. To carry out this procedure, the UGE of 6 different test tissues were analyzed for *ERCC1* expression using the TaqMan® methodology described above. The internal control gene β -actin and the calibrator RNA, Human Liver Total RNA (Stratagene, Cat. #735017) was used.

The known relative *ERCC1* expression level of each sample AG221, AG222, AG252, Adult Lung, PC3, AdCol was divided by its corresponding TaqMan® derived UGE to yield an unaveraged correction factor K.

$$K_{unaveraged} = \text{Known Values} / \text{UGE}$$

Next, all of the K values are averaged to determine a single K_{ERCC1} correction factor specific for *ERCC1*, Human Liver Total RNA (Stratagene, Cat. #735017) from calibrator RNA and β -actin.

Therefore, to determine the Corrected Relative *ERCC1* Expression in an unknown tissue sample on a scale that is consistent with pre-TaqMan® *ERCC1* expression studies, one merely multiplies the uncorrected gene expression data (UGE) derived from the TaqMan® apparatus with the K_{ERCC1} specific correction

factor, given the use of the same internal control gene and calibrator RNA.

$$\text{Corrected Relative } ERCC1 \text{ Expression} = UGE \times K_{ERCC1}$$

A K_{ERCC1} may be determined using any accurately pre-quantified calibrator
5 RNA or internal control gene. Future sources of accurately pre-quantified RNA can
be calibrated to samples with known relative *ERCC1* expression levels as described
in the method above or may now be calibrated against a previously calibrated
calibrator RNA such as Human Liver Total RNA (Stratagene, Cat. #735017)
described above.

10 For example, if a subsequent K_{ERCC1} is determined for a different internal
control gene and/or a different calibrator RNA, one must calibrate both the internal
control gene and the calibrator RNA to tissue samples for which *ERCC1* expression
levels relative to that particular internal control gene have already been determined.
Such a determination can be made using standard pre-TaqMan®, quantitative RT-
15 PCR techniques well known in the art. The known expression levels for these
samples will be divided by their corresponding UGE levels to determine a K for that
sample. K values are then averaged depending on the number of known samples to
determine a new K_{ERCC1} specific to the different internal control gene and/or
calibrator RNA.

20 EXAMPLE 4

Determining the Uncorrected Gene Expression (UGE) for TS

Two pairs of parallel reactions are carried out. The "test" reactions and the
"calibration" reactions. Figure 8. The *TS* amplification reaction and the β -actin

internal control amplification reaction are the test reactions. Separate *TS* and β -actin amplification reactions are performed on the calibrator RNA template and are referred to as the calibration reactions. The TaqMan® instrument will yield four different cycle threshold (Ct) values: Ct_{TS} and $Ct_{\beta-actin}$ from the test reactions and Ct_{TS} and $Ct_{\beta-actin}$ from the calibration reactions. The differences in Ct values for the two reactions are determined according to the following equation:

$$\begin{aligned}\Delta Ct_{test} &= Ct_{TS} - Ct_{\beta-actin} && \text{(From the "test" reaction)} \\ \Delta Ct_{calibrator} &= Ct_{TS} - Ct_{\beta-actin} && \text{(From the "calibration" reaction)}\end{aligned}$$

Next the step involves raising the number 2 to the negative ΔCt , according to the following equations.

$$\begin{aligned}2^{-\Delta Ct_{test}} &&& \text{(From the "test" reaction)} \\ 2^{-\Delta Ct_{calibrator}} &&& \text{(From the "calibration" reaction)}\end{aligned}$$

In order to then obtain an uncorrected gene expression for *TS* from the TaqMan® instrument the following calculation is carried out:

$$\text{Uncorrected gene expression (UGE) for } TS = 2^{-\Delta Ct_{test}} / 2^{-\Delta Ct_{calibrator}}$$

Normalizing UGE with known relative TS expression levels

The normalization calculation entails a multiplication of the UGE with a correction factor (K_{TS}) specific to *TS* and a particular calibrator RNA. A correction factor K_{TS} can also be determined for any internal control gene and any accurately pre-quantified calibrator RNA. Preferably, the internal control gene β -actin and the accurately pre-quantified calibrator RNA, Universal PE RNA; Cat #4307281, lot # 3617812014 from Applied Biosystems are used. Given these reagents correction

factor K_{TS} equals 12.6×10^{-3} .

Normalization is accomplished using a modification of the ΔCt method described by Applied Biosystems, the TaqMan® manufacturer, in User Bulletin #2 and described above. To carry out this procedure, the UGE of 6 different previously published test tissues were analyzed for *TS* expression using the TaqMan® methodology described above. These tissue samples are described in Salonga, *et al.*, Clinical Cancer Research, 6:1322-1327, 2000, which is hereby incorporated by reference in its entirety. The internal control gene β -actin and the calibrator RNA, Universal PE RNA; Cat #4307281, lot # 3617812014 from Applied Biosystems was used.

The previously published relative *TS* expression level of each sample L7, L91, L121, L150, L220, L164 was divided by its corresponding TaqMan® derived UGE to yield an unaveraged correction factor K . Salonga, *et al.*, Clinical Cancer Research, 6:1322-1327, 2000, incorporated herein by reference in its entirety.

$$K_{\text{unaveraged}} = \text{Known Values} / \text{UGE}$$

Next, all of the K values are averaged to determine a single K_{ERCC1} correction factor specific for *TS*, Applied Biosystems Universal PE RNA; Cat #4307281, lot # 3617812014 calibrator RNA, and β -actin.

Therefore, to determine the Corrected Relative *TS* Expression in an unknown tissue sample on a scale that is consistent with pre-TaqMan® *TS* expression studies, one merely multiplies the uncorrected gene expression data (UGE) derived from the TaqMan® apparatus with the K_{TS} specific correction factor, given the use of the

same internal control gene and calibrator RNA.

$$\text{Corrected Relative } TS \text{ Expression} = UGE \times K_{TS}$$

A K_{TS} may be determined using any accurately pre-quantified calibrator

- 5 RNA or internal control gene. Future sources of accurately pre-quantified RNA can be calibrated to samples with known relative *ERCC1* expression levels as described in the method above or may now be calibrated against a previously calibrated calibrator RNA such as Universal PE RNA; Cat #4307281, lot # 3617812014 from Applied Biosystems described above.
- 10 For example, if a subsequent K_{TS} is determined for a different internal control gene and/or a different calibrator RNA, one must calibrate both the internal control gene and the calibrator RNA to tissue samples for which *TS* expression levels relative to that particular internal control gene have already been determined or published. Such a determination can be made using standard pre-TaqMan®,
- 15 quantitative RT-PCR techniques well known in the art. The known expression levels for these samples will be divided by their corresponding UGE levels to determine a K for that sample. K values are then averaged depending on the number of known samples to determine a new K_{TS} specific to the different internal control gene and/or calibrator RNA.

20 EXAMPLE 5

Patient Selection and Chemotherapy Treatment

All patients were enrolled in the compassionate protocol 3C-98-3 at the University of Southern California Medical Center from 1998-2000 and received the

following oxaliplatin/5-FU combination therapy regimen: 130 mg/m² oxaliplatin plus continuous infusion of 5-FU. All patients had failed a prior treatment with 5-FU and 60% (30/50) had failed an additional second line treatment with irinotecan (CPT-11). All patients showed active disease in stage IV colorectal cancer at time of
5 protocol entry.

Clinical Evaluation and Response Criteria

During chemotherapy, weekly evaluations were recorded for performance status, weight, abdominal pain, complete blood counts, and serum creatinine and blood urea nitrogen levels. Tumor burden is measured using computed tomography
10 (CT). A bi-dimensionally measurable tumor mass was required at the time of protocol entry. Responders to therapy were classified as those patients whose tumor burden was decreased by 50% or more for at least 6 weeks. Non-responders included those with stable disease or cancer progression. Survival was computed as the number of days from the initiation of chemotherapy with 5-FU/oxaliplatin to death
15 of any cause. Patients who were alive at the last follow-up evaluation were censored at that time.

Statistical Analysis

TaqMan® analyses yield levels that are expressed as ratios between two absolute measurements (gene of interest : internal reference gene). The Mann-
20 Whitney test and Kruskal-Wallis test were used to evaluate the associations of *TS* and *ERCC1* expression (as continuous variables) with patients demographics. Zar, Biostatistical Analysis. Prentice-Hall, Inc Englewood Cliffs, N.J. (1974), pp. 109-114 and 139-142, respectively. The maximal chi-square method of Miller and Sigmund (Biometrics 38: 1011-1016, 1982) and Halpern (Biometrics 38: 1017-

1023, 1982), was adapted to determine which cut-off threshold level best dichotomized patients into low and high *TS* and *ERCC1* expression subgroups. Pearson's chi-square test was used to assess the associations between the dichotomized molecular markers and to response to chemotherapy Zar, Biostatistical Analysis. Prentice-Hall, Inc Englewood Cliffs, N.J. (1974), pp.59-68. Hazard ratios were used to calculate the relative risks of death. Schulman, Infection Control & Hospital Epidemiology, 18:65-73, 1997. These calculations were based on the Pike estimate, with the use of the observed and expected number of events as calculated in the log-rank test statistic (Pike, J R Stat Soc Series A 135: 201-203, 1972). To determine a *P* value that would be interpreted as a measure of the strength of the association based on the maximal chi-square analysis, 1000 boot-strap-like simulations were used to estimate the distribution of the maximal chi-square statistics under the hypothesis of no association. (Halpern, Biometrics 38: 1017-1023, 1982). The level of significance was set to $p < 0.05$.

15 *Demographics and patients available for response and survival evaluation*

A total of 50 patients, consisting of 14 (28%) women and 36 (72%) men, with a median age of 59 (min.:34; max.:83) years were evaluated in this study. The ethnic backgrounds of this group included 39 Caucasians, 6 Hispanics, 3 Asians, and 2 African-Americans. All 50 patients were assessable to associate *TS* expression and

20 *ERCC1* expression levels with survival. Forty-five (90%) were assessable to test the association of this molecular parameters with response by above cited criteria.

TS expression levels and ERCC1 expression levels

Total mRNA was isolated from microdissected FPE pretreatment tumor samples, and relative mRNA expression levels of *ERCC1* : β -actin and or *TS* : β -

actin were measured using quantitative RT-PCR. A method for mRNA isolation from such samples is described in Example 1 and in US Patent Application No. 09/469,338, filed December 20, 1999, and is hereby incorporated by reference in its entirety. A reverse transcription/polymerase chain reaction (RT/PCR)-based assay
5 system was used to determine the level of expression of *ERCC1*, and β -actin, as described in Example 2. Corrected relative *ERCC1* and/or *TS* expression was determined as described in Examples 3 and 4, respectively.

TS gene expression was detectable in all 50 samples analyzed. The median corrected *TS* expression, relative to the housekeeping gene, β -Actin, was 3.4×10^{-3}
10 (min.: 0.18×10^{-3} ; max.: 11.5×10^{-3}). Corrected *ERCC1* gene expression was detectable in 47 (94%) samples analyzed. The median corrected *ERCC1* gene expression was 2.53×10^{-3} (min.: 0.00; max.: 14.61×10^{-3}). When analyzed by gender, age, and ethnic origin, no significant differences in corrected *TS* and *ERCC1* mRNA expression were found.

15 *Survival in relation to TS expression*

With a median follow-up period of 10.5 months (95% C.I.: 1.8, 21.2) for the 50 patients analyzed in this study, the median survival was 8.4 months (95% C.I.: 6.4, 12.3). Using a *TS* threshold value of 7.5×10^{-3} , 43 (86%) patients had a low corrected *TS* expression level, and 7 (14%) patients had a high corrected *TS* expression
20 level. The log-rank test was used to evaluate the association between corrected *TS* gene expression and survival. The respective survival curves are presented in figure 1 and show a median survival of 10.2 months (95% C.I.: 7.4, 15.1) in the low corrected *TS* expressor group, and 1.5 months (95% C.I.: 1.1, 2.1) in the high corrected *TS* expression

group ($P < 0.001$; Logrank Test). The probability of survival at 6 months was 0.77 for patients with corrected *TS* expression $\leq 7.5 \times 10^{-3}$ compared to 0.00 for the high expressor group. Patients with corrected *TS* levels $> 7.5 \times 10^{-3}$ had a 8.4 (95%CI: 2.63, 27.13) fold increased relative risk of dying compared to patients with *TS* levels $\leq 7.5 \times 10^{-3}$ in the univariate analysis ($p < 0.001$, Figure 4).

Survival in relation to ERCC1 expression

Using 4.9×10^{-3} as a threshold, 40 (80%) had a low corrected *ERCC1* expression and 10 (20%) had a high corrected *ERCC1* expression. Figure 2 displays a Kaplan Meier plot of the estimated probability of survival versus corrected *ERCC1* expression levels, and shows a median survival of 10.2 months (95% C.I.: 7.8, 15.1) for the low expressor group and 1.9 months (95% C.I.: 1.1, 4.9) for the high expressor group ($P < 0.001$; Logrank Test). The probability of survival at 6 months was 0.76 for patients with corrected *ERCC1* expression $\leq 4.9 \times 10^{-3}$ compared to 0.16 for patients with corrected *ERCC1* expression $> 4.9 \times 10^{-3}$. Patients with corrected *ERCC1* levels $> 4.9 \times 10^{-3}$ had a 4.8 (95%CI: 2.09, 15.88) fold increased relative risk of dying compared to patients with corrected *ERCC1* levels $\leq 4.9 \times 10^{-3}$ in the univariate analysis ($p < 0.001$; Figure 4).

Survival in relation to combined ERCC1 and TS expression

Low corrected *TS* and *ERCC1* expression levels were detected in 36 (72%) of the patients, and 14 (28%) patients had high corrected *TS* and/or *ERCC1* expression level. Patients with low expression levels for both genes had a significant superior survival. The median survival was 11.1 months (95% C.I.: 8.4, 17.5) for the low corrected *TS* and *ERCC1* expressors, and 1.9 months (95% C.I.: 1.1, 4.9) for the high corrected *TS* and/or *ERCC1* expressors ($P < 0.001$, Logrank Test; Figure 3). Patients with low

corrected expression levels for both genes had a probability of survival at 6 months of 0.85 compared to 0.10 for the patients with a high corrected expression level for at least one gene, *TS* or *ERCC1*. The relative risk of dying for patients with an increased corrected expression for at least one gene (*TS* or *ERCC1*) was 7.12 (95%CI: 2.60, 19.52) compared to patients, which showed low expression levels for both genes in the tumor (P<0.001; Figure 4). *TS* and *ERCC1* mRNA expression are independent of each other as revealed by the stratified analysis (Figure 5).

Association of response with TS and ERCC1 gene expression levels.

The median corrected *TS* expression level was 3.4×10^{-3} (min.: 0.18×10^{-3} ; max.: 11.50×10^{-3}) for the 45 measurable patients and is identical to the entire 50 patient-cohort. When responses were analyzed by segregating tumors into low- and high *TS* expressors, three out of four (75%) partial responders, 26 of 27 (96%) of patients with stable disease, and 9 of 14 (64%) of patients with progressive disease had a low corrected *TS* expression (P=0.02; Fisher's Exact Test; Figure 9).

The median corrected *ERCC1* expression level was 2.7×10^{-3} (min.: 0.00; max.: 14.61×10^{-3}) for the 45 measurable patients and not significantly different to the entire 50 patient-cohort. However the *ERCC1* expression level was not statistically significant associated with response to chemotherapy (p=0.29, Fisher's Exact Test).

What is claimed is:

1. A method for determining a chemotherapeutic regimen comprising 5-Fluorouracil, oxaliplatin, or combination thereof for treating a tumor in a patient comprising:
 - 5 (a) obtaining a tissue sample of the tumor and fixing the sample, to obtain a fixed tumor sample;
 - (b) isolating mRNA from the fixed tumor sample;
 - (c) subjecting the mRNA to amplification using either a pair of oligonucleotide primers that hybridize under stringent conditions to a region of the *ERCC1*
10 gene, or a pair of oligonucleotide primers that hybridize under stringent conditions to a region of the *TS* gene, to obtain an *ERCC1* or *TS* amplified sample;
 - (d) determining the amount of *TS* or *ERCC1* mRNA in the amplified sample;
 - (e) comparing the amount of *TS* or *ERCC1* mRNA from step (d) to an amount
15 of mRNA of an internal control gene; and
 - (f) determining a chemotherapeutic regime comprising 5-fluorouracil, oxaliplatin, or combination thereof based on the amount of *TS* and/or *ERCC1* mRNA in the amplified sample and the threshold level for *TS* and/or *ERCC1* gene expression.

2. A method for determining a chemotherapeutic regimen comprising 5-Fluorouracil, oxaliplatin, or combination thereof for treating a tumor in a patient comprising:
- (a) obtaining a tissue sample of the tumor and fixing the sample, to
5 obtain a fixed tumor sample;
 - (b) isolating mRNA from the fixed tumor sample;
 - (c) subjecting the mRNA to amplification using a pair of oligonucleotide primers that hybridize under stringent conditions to a region of the *ERCC1* gene, to obtain an amplified sample;
 - 10 (d) determining the amount of *ERCC1* mRNA in the amplified sample;
 - (e) comparing the amount of *ERCC1* mRNA from step (d) to an amount of mRNA of an internal control gene; and
 - (f) determining a chemotherapeutic regime comprising 5-fluorouracil, oxaliplatin, or combination thereof based on the amount of *ERCC1*
15 mRNA in the amplified sample and the threshold level for *ERCC1* gene expression.
3. A method for determining a chemotherapeutic regimen comprising 5-Fluorouracil, oxaliplatin, or combination thereof for treating a tumor in a patient comprising:
- 20 (a) obtaining a tissue sample of the tumor and fixing the sample, to obtain a fixed tumor sample;
 - (b) isolating mRNA from the fixed tumor sample;

- (c) subjecting the mRNA to amplification using a pair of oligonucleotide primers that hybridize under stringent conditions to a region of the *TS* gene, to obtain an amplified sample;
- (d) determining the amount of *TS* mRNA in the amplified sample;
- 5 (e) comparing the amount of *TS* mRNA from step (d) to an amount of mRNA of an internal control gene; and
- (f) determining a chemotherapeutic regime comprising 5-fluorouracil, oxaliplatin, or combination thereof based on the amount of *TS* mRNA in the amplified sample and the threshold level for *TS* gene
- 10 expression.
4. A method for determining a chemotherapeutic regimen comprising 5-Fluorouracil, oxaliplatin, or combination thereof for treating a tumor in a patient comprising:
- (a) obtaining a tissue sample of the tumor and fixing the sample, to
- 15 obtain a fixed tumor sample;
- (b) isolating mRNA from the fixed tumor sample;
- (c) subjecting the mRNA to amplification using a pair of oligonucleotide primers that hybridize under stringent conditions to a region of the *ERCC1* gene, and a pair of oligonucleotide primers that hybridize
- 20 under stringent conditions to a region of the *TS* gene, to obtain an *ERCC1* and a *TS* amplified sample;
- (d) determining the amount of *TS* and *ERCC1* mRNA in the amplified sample;

- (e) comparing the amount of *TS* and *ERCC1* mRNA from step (d) to an amount of mRNA of an internal control gene; and
- (f) determining a chemotherapeutic regime comprising 5-fluorouracil, oxaliplatin, or combination thereof based on the amount of *TS* and/or *ERCC1* mRNA in the amplified sample and the threshold level for *TS* and/or *ERCC1* gene expression.

- 5. The method of any one of claims 1, 2, 3, or 4 wherein the oligonucleotide primers consist of the oligonucleotide primer pair *ERCC1*, or pair of oligonucleotide primers substantially identical thereto.
- 10 6. The method of claim 3 wherein the oligonucleotide primers consist of the oligonucleotide primer pair *TS*, or pair of oligonucleotide primers substantially identical thereto.
- 7. The method of any one of claims 1, 2, 3, or 4 wherein the tumor is a colorectal adenocarcinoma tumor.
- 15 8. The method of claim 4 wherein the primers consist of both the oligonucleotide primer pair *TS* and oligonucleotide primer pair *ERCC1*.
- 9. The method of any one of claims 1, 2, or 4 wherein the threshold level of *ERCC1* gene expression is about 4.9 times an internal control gene expression level.

10. The method of any one of claims 1, 3, or 4 wherein, the threshold level of *TS* gene expression is about 7.5 times an internal control gene expression level.
11. The method of any one of claims 1, 2, 3, or 4 wherein the internal control gene is β -actin
- 5 12. A method for determining the level of *ERCC1* expression in a fixed paraffin embedded tissue sample comprising;
 - (a) deparaffinizing the tissue sample, to obtain a deparaffinized sample;
 - (b) isolating mRNA from the deparaffinized sample in the presence of an effective amount of a chaotropic agent;
 - 10 (c) subjecting the mRNA to amplification using a pair of oligonucleotide primers that hybridize under stringent conditions to a region of the *ERCC1* gene, to obtain an amplified sample;
 - (d) determining the quantity of *ERCC1* mRNA relative to the quantity of mRNA of an internal control gene.
- 15 13. The method of claim 12 wherein, the pair of oligonucleotide primers consists of the oligonucleotide primer pair ERCC1 or a pair of oligonucleotide primers substantially similar thereto.

14. A method for determining the level of *TS* expression in a fixed paraffin embedded tissue sample comprising;
- (a) deparaffinizing the tissue sample, to obtain a deparaffinized sample;
- (b) isolating mRNA from the deparaffinized sample in the presence of an effective amount of a chaotropic agent;
- (c) subjecting the mRNA to amplification using a pair of oligonucleotide primers that hybridize under stringent conditions to a region of the *TS* gene, to obtain an amplified sample;
- (d) determining the quantity of *TS* mRNA relative to the quantity of mRNA of an internal control gene.
15. The method of claim 14 wherein, the pair of oligonucleotide primers consists of the oligonucleotide primer pair TS or a pair of oligonucleotide primers substantially similar thereto.
16. The method of claim 12 or 14 wherein the internal control gene is β -actin.
17. The method of claim 12 or 14 wherein, mRNA isolation is carried out by
- (a) heating the tissue sample in a solution comprising an effective concentration of a chaotropic compound to a temperature in the range of about 75 to about 100 °C for a time period of about 5 to about 120 minutes;
- and
- (b) recovering said mRNA from the chaotropic solution.

18. An oligonucleotide primer having the sequence of SEQ ID NO: 1 or and an oligonucleotide substantially identical thereto.
19. An oligonucleotide primer having the sequence of SEQ ID NO: 2 or and an
5 oligonucleotide substantially identical thereto.
20. An oligonucleotide primer having the sequence of SEQ ID NO: 3 or and an oligonucleotide substantially identical thereto.
21. An oligonucleotide primer having the sequence of SEQ ID NO: 4 or and an oligonucleotide substantially identical thereto.
- 10 22. A kit for detecting expression of an *ERCC1* gene comprising oligonucleotide pair ERCC1 or an oligonucleotide pair substantially identical thereto.
23. A kit for detecting expression of a *TS* gene comprising oligonucleotide pair TS or an oligonucleotide pair substantially identical thereto.
- 15 24. A kit for detecting expression of a *TS* and *ERCC1* gene comprising oligonucleotide pair TS or an oligonucleotide pair substantially identical thereto and oligonucleotide pair ERCC1 or an oligonucleotide pair substantially identical thereto.

Figure 1




Figure 2




Figure 3




Figure 4 Analysis of Survival of Patients with Colorectal Cancer: Association with *TS* and *ERCC1* mRNA expression (univariate analysis)

Factor	No. Pts.	Relative Risk ¹	Probability of Survival at 6 Months	p-value ²
<i>TS</i> -Expression				<0.001
Low (< 7.5)	43	1.00	0.77 ± 0.07	
High (>7.5)	7	8.44 (2.63,27.13) ³	0.00 ± 0.00	
<i>ERCC1</i> -Expression				<0.001
Low (< 4.9)	40	1.00	0.76 ± 0.07	
High (> 4.9)	10	5.76 (2.09,15.88) ³	0.16 ± 0.14	
<i>TS</i> and <i>ERCC1</i> Expression				<0.001
<i>TS</i> and <i>ERCC1</i> Low	36	1.00	0.85 ± 0.06	
Others	14	7.12 (2.60,19.52) ³	0.10 ± 0.10	

1. Relative risk can be thought as the average increased chance of dying at any point in the time for patients in the second group compared to those in the first group. The group with better prognosis is listed first.
2. Based on logrank test statistics, but after 1,000 bootstrap simulation to adjust for selection of optimal cut-point.
3. 95% confidence interval

Figure 5 Analysis of survival of Patients with colorectal cancer: correlation with *TS* and *ERCC1* mRNA expression (stratified analysis)

Expression	Stratified by	Relative risk ¹	95% CI ²	Adjusted p-value ³
<i>TS</i>	<i>ERCC1</i>			0.002
	Low	1.00		
	High	5.38	(1.46, 19.92)	
<i>ERCC1</i>	<i>TS</i>			0.008
	Low	1.00		
	High	4.24	(1.35, 13.29)	

1. Relative risk can be thought as the average increased chance of dying at any point in time for patients in the second group compared to those in the first group. The group with better prognosis is listed first.
2. 95% confidence interval
3. Based on logrank test statistic, but after 1,000 bootstrap simulation to adjust for selection of optimal cut point.

Figure 6 Response in relation to ERCC1 and TS expression.





Figure 7: Chart illustrating how to calculate *ERCC1* expression relative to an internal control gene

Sample	C_T	C_T	ΔC_T	$2^{-\Delta C_T}$	C_T	C_T	ΔC_T	$2^{-\Delta C_T}$	$2^{-\Delta C_T}$	$2^{-\Delta C_T}$	K	K_{GIST1}
	fact	re-m			fact	re-m						
Experimental	unknown 1	26.68	21.17	7.51	0.00549	-	-	-	0.737	-	-	1.54×10^3
	unknown 2	24.8	17.64	7.16	0.00899	-	-	-	0.8395	-	-	1.54×10^3
Calib. RNA	-	-	-	-	-	27.81	20.71	7.07	0.0074	$0.00740/0.0074 = 1$	-	-
	-	-	-	-	-	-	-	-	-	-	-	-
From known samples	AC221	34.48	28.58	5.9	0.187	-	-	-	2.81	4.32×10^3	1.54×10^3	1.54×10^3
	AC222	33.93	27.21	6.72	0.0095	-	-	-	1.59	2.45×10^3	1.54×10^3	1.54×10^3
	AC252	38.9	28.43	7.47	0.0056	-	-	-	0.946	1.48×10^3	1.54×10^3	1.54×10^3
	Adult lung	25.2	17.3	8	0.0039	-	-	-	0.635	1.009×10^3	1.54×10^3	1.54×10^3
	PC3	24.31	16.47	6.04	0.0038	-	-	-	0.637	0.881×10^3	1.54×10^3	1.54×10^3
	Adipol	24.46	16.75	7.71	0.0046	-	-	-	0.801	1.233×10^3	1.54×10^3	1.54×10^3
Calib. RNA	-	-	-	-	-	25.88	18.57	7.39	0.00586/ $0.00586 = 1$	-	-	-

Figure 8: Chart illustrating how to calculate *TS* expression relative to an internal control gene

Sample	C_T	n	C_T	$p\text{-val}$	ΔC_T	$2^{-\Delta C_T}$	C_T	n	C_T	$p\text{-val}$	ΔC_T	$2^{-\Delta C_T}$	$2^{-\Delta C_T/2}$	$2^{-\Delta C_T/2}$	K	M_{10}	$2^{-\Delta C_T/2}$
Experimental	unknown 1	26.14	18.35	8.79	0.00603	-	-	-	-	-	-	-	0.178	-	-	12.8×10^3	2.25×10^4
	unknown 2	32.07	26.39	5.69	0.0748	-	-	-	-	-	-	-	1.33	-	-	12.6×10^3	16.756×10^4
	Ctrl. RNA	-	-	-	-	-	27.94	23.78	4.15	0.0663	0.0560, 0.0661	-	-	-	-	-	-
From Published Data	L7	26.94	24.55	2.39	0.191	-	-	-	-	-	-	-	3.18	-	36.8×10^4	12.2×10^3	12.6×10^3
	L91	24.91	22.12	2.79	0.144	-	-	-	-	-	-	-	2.40	-	29.55×10^4	12.31×10^3	12.6×10^3
	L121	24.95	20.89	4.06	0.059	-	-	-	-	-	-	-	0.88	-	12.22×10^4	13.88×10^3	12.6×10^3
	L150	29.77	22.88	6.89	0.008	-	-	-	-	-	-	-	0.133	-	1.72×10^4	12.93×10^3	12.6×10^3
	L220	26.52	18.77	6.75	0.0092	-	-	-	-	-	-	-	0.153	-	1.89×10^4	12.35×10^3	12.6×10^3
	L164	26.81	21.21	5.6	0.0205	-	-	-	-	-	-	-	0.341	-	4.2×10^4	12.31×10^3	12.6×10^3
	Ctrl. RNA	-	-	-	-	-	26.14	20.09	5.04	0.06	0.060, 0.061	-	-	-	-	-	-

Fig. 9: CPT-11/C 225 Mediated Tumor Response and EGF-R Gene Expression



SEQUENCE LISTING

<110> Kathleen Danenberg, et al.

<120> METHOD OF DETERMINING A CHEMOTHERAPEUTIC
REGIMEN BASED ON ERCC1 and TS EXPRESSION

<130> 11220-119

<140> To be Assigned

<141> 2001-03-09

<160> 11

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Primer

<400> 1

gggaatttgg cgacgtaatt c

21

<210> 2

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Primer

<400> 2

gcggaggctg aggaacga

18

<210> 3

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Primer

<400> 3

ggcctcgggtg tgccttt

17

<210> 4

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Primer

<400> 4

gatgtgcgca atcatgtacg t

21

<210> 5

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Probe

<400> 5

cacaggtgct ctggcccagc acata

25

<210> 6

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Primer

<400> 6

aacatcgcca gctacgccct gc

22

<210> 7

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Probe

<400> 7

accaccacgg ccgagcgg

18

<210> 8

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Probe

<400> 8

tgagcgcggc tacagctt

18

<210> 9

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide Primer

<400> 9

tccttaatgt cagcacgat tt

22

<210> 10

<211> 1097

<212> DNA

<213> Homo sapiens

<400> 10

aagtgtgtgc agccctgggc cacgctggcc gtgctggcag tgggcccgcct cgatccctct 60
gcagtctttc ccttgaggct ccaagaccag caggtgaggc ctgcgcggcg tgaaaccgtg 120
aggcccggac cacaggctcc agatggaccc tgggaaggac aaagaggggg tgccccagcc 180
ctcagggccg ccagcaagga agaaatttgt gatacccctc gacgaggatg aggtccctcc 240
tggagtggcc aagcccttat tccgatctac acagagcctt cccactgtgg acacctcggc 300
ccaggcggcc cctcagacct acgccgaata tgccatctca cagcctctgg aaggggctgg 360
ggccacgtgc ccacacagggt cagagccccct ggcaggagag acgcccaccc aggccctgaa 420
accgggggca aaatccaaca gcatcattgt gagccctcgg cagaggggca atcccgtact 480
gaagttcgtg cgcaatgtgc cctgggaatt tggcgacgta attcccgtact atgtgctggg 540
ccagagcacc tgtgccctgt tcctcagcct ccgctaccac aacctgcacc cagactacat 600

```

ccatggggcgg ctgcagagcc tggggaagaa cttgcgccttg cgggtcctgc ttgtccaggt 660
ggatgtgaaa gatccccagc agggccctcaa ggagctggct aagatgtgta tcctggccga 720
ctgcacattg atcctcgcct ggagccccga ggaagctggg cggtagctgg agacctaca 780
ggcctatgag cagaaaccag cggacctcct gatggagaag cttagagcagg acttcgtctc 840
ccgggtgact gaatgtctga ccacogtgaa gtcagtcaac aaaacggaca gtcagaccct 900
cctgaccaca tttggatctc tggaaacagc catcgccgca tcaagagaag atctgggctt 960
atgcccaggc ctgggcccctc agaaagcccg gaggctgttt gatgtcctgc acgagccctt 1020
cttgaaagta ccctgatgac cccagctgcc aaggaaaccc ccagtgtaat aataaatcgt 1080
cctcccaggc caggctc 1097

```

<210> 11

<211> 1536

<212> DNA

<213> Homo sapiens

<400> 11

```

ggggggggggg ggaccacttg gcctgcctcc gtcccgccgc gccacttggc ctgcctccgt 60
cccgccgcgc cacttcgcct gcctccgtcc cccgcccgc gccatgcc tgtggccggc 120
tcggagctgc cgcgcgggcc cttgcccccc gccgcacagg agcgggacgc cgagcccggt 180
ccgcccgcacg gggagctgca gtacctgggg cagatccaac acatcctccg ctgcccggct 240
aggaaggacg accgcacggg caccggcacc ctgtcgggtat tcggcatgca ggcgcgctac 300
agcctgagag atgaattccc tctgctgaca accaaacgtg tgttctggaa ggggtgtttg 360
gaggagttgc tgtggtttat caagggatcc acaaatgcta aagagctgtc ttccaaggga 420
gtgaaaatct gggatgccaa tggatcccga gactttttgg acagcctggg attetccacc 480
agagaagaag gggacttggg ccagtttat ggcttcagt ggaggcattt tggggcagaa 540
tacagagata tggaaatcaga ttattcagga caggagttg accaactgca aagagtgtt 600
gacaccatca aaaccaaccc tgacgacaga agaatcatca tgtgcgcttg gaatccaaga 660
gatcttcctc tgatggcgct gcctccatgc catgccctct gccagttcta tgtgggtgaa 720
agtgcgctgt cctgccagct gtaccagaga tcgggagaca tgggcctcgg tgtgcctttc 780
aacatcgcca gctacgccct gctcacgtac atgattgccc acatcacggg cctgaagcca 840
ggtgacttta tacacacttt gggagatgca catatttacc tgaatcacat cgagccactg 900
aaaattcagc ttcagcgaga acccagacct tcccaaagc tcaggattct tcgaaaagtt 960
gagaaaattg atgacttcaa agctgaagac tttcagattg aagggtacaa tccgcatcca 1020
actattaaaa tggaaatggc tgtttagggt gctttcaaag gagcttgaag gatattgtca 1080
gtctttaggg gttagggctg atgccgaggt aaaagttctt tttgctctaa aagaaaaagg 1140
aactagggtca aaaatctgtc cgtgacctat cagttattaa ttttaaggga tgttgccact 1200
ggcaaatgta actgtgccag ttctttccat aataaaaggc tttgagttaa ctactgagg 1260
gtatctgaca atgctgaggt tatgaacaaa gtgaggagaa tgaaatgtat gtgctcttag 1320
caaaaacatg tatgtgcatt tcaatcccac gtacttataa agaaggttgg tgaatttcac 1380
aagctatttt tggaatattt ttagaatatt ttaagaattt cacaagctat tccctcaaat 1440
ctgagggagc tgagtaacac catcgatcat gatgtagagt gtggttatga actttatagt 1500
tgttttatat gttgctataa taaagaagtg ttctgc 1536

```

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 July 2002 (25.07.2002)

PCT

(10) International Publication Number
WO 02/057489 A3

(51) International Patent Classification⁷: C12Q 1/68,
G01N 33/574, 33/50

(21) International Application Number: PCT/US01/43039

(22) International Filing Date:
9 November 2001 (09.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/250,358 1 December 2000 (01.12.2000) US
60/250,471 4 December 2000 (04.12.2000) US
09/877,178 11 June 2001 (11.06.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant: RESPONSE GENETICS, INC. [US/US];
1640 Marengo Street, 6th Floor, Los Angeles, CA 90033
(US).

Published:
— with international search report

(72) Inventor: DANENBERG, Kathleen, D.; 3367 Rubio
Crest Drive, Altadena, CA 91001 (US).

(88) Date of publication of the international search report:
6 November 2003

(74) Agents: MELORO, Thomas, J. et al.; Kenyon & Kenyon,
Suite 700, 1500 K Street N.W., Washington, DC 20005
(US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/057489 A3

(54) Title: METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON ERCC1 AND TS EXPRESSION

(57) Abstract: The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and/or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively.

INTERNATIONAL SEARCH REPORT

Internal Classification No
PCT/US 01/43039

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68 G01N33/574 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, MEDLINE, CHEM ABS Data, WPI Data, PAJ, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	METZGER R ET AL: "ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy" JOURNAL OF CLINICAL ONCOLOGY, PHILADELPHIA, PA, US, vol. 16, no. 1, January 1998 (1998-01), pages 309-316, XP002226040	1-6, 8-11, 18-24
Y	abstract page 310, column 2, paragraph 1 - paragraph 5 page 312, column 1, paragraph 3 -page 315, column 2, paragraph 1; figures 2-6; tables 1,2 --- -/-	12-16

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

17 July 2003

Date of mailing of the international search report

31/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Tilkorn, A-C

INTERNATIONAL SEARCH REPORT

Internal application No
PCT/US 01/43039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 705 336 A (DABHOLKAR MEENAKSHI ET AL) 6 January 1998 (1998-01-06) cited in the application	2,5,9, 11,18, 19,22
Y	abstract column 1, line 65 -column 2, line 29 column 3, line 21 -column 4, line 67 column 5, line 48 -column 6, line 64 column 7, line 9 -column 10, line 11; figures 2-5	12,13,16
X	BRITTEN R A ET AL: "ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells" INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 89, no. 5, 2000, pages 453-457, XP002226041 ISSN: 0020-7136	2,9-11
Y	abstract page 454, column 1, paragraph 3 -column 2, paragraph 2 page 455, column 1, paragraph 2 -page 457, column 2, paragraph 1; figure 1; table 1	12,13,16
X	OMURA KENJI ET AL: "Quantification of thymidylate synthase gene expression in human gastrointestinal carcinoma tissues using competitive PCR." HEPATO-GASTROENTEROLOGY, vol. 46, no. 26, March 1999 (1999-03), pages 985-990, XP009013766 ISSN: 0172-6390	1,2,6,7, 10,11, 20,21,23
Y	abstract page 986, column 1, paragraph 2 -page 987, column 1, paragraph 3 page 987, column 2, paragraph 3 -page 989, column 2, paragraph 3	14-16
X	HOUZE THOMAS A ET AL: "Detection of thymidylate synthase gene expression levels in formalin-fixed paraffin embedded tissue by semiquantitative, nonradioactive reverse transcriptase polymerase chain reaction." TUMOR BIOLOGY, vol. 18, no. 1, 1997, pages 53-68, XP009013753 ISSN: 1010-4283	20,21
A	table 1 the whole document	1,3,6,7, 10-17,23

-/--

INTERNATIONAL SEARCH REPORT

Internationa Application No
PCT/US 01/43039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GODFREY T E ET AL: "Quantitative mRNA expression analysis from formalin-fixed, paraffin-embedded tissues using 5' nuclease quantitative reverse transcription-polymerase chain reaction" JOURNAL OF MOLECULAR DIAGNOSTICS, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, vol. 2, no. 2, May 2000 (2000-05), pages 84-91, XP002226042 the whole document	12-16
Y	KOOPMANS M ET AL: "OPTIMIZATION OF EXTRACTION AND PCR AMPLIFICATION OF RNA EXTRACTS FROM PARAFFIN-EMBEDDED TISSUE IN DIFFERENT FIXATIVES" JOURNAL OF VIROLOGICAL METHODS, AMSTERDAM, NL, vol. 43, no. 2, 1993, pages 189-204, XP000997425 ISSN: 0166-0934 abstract page 193, paragraph 2 -page 194, paragraph 2; figure 1 page 197, paragraph 1 -page 200, paragraph 2	12-16
A	DUIN VAN M ET AL: "MOLECULAR CHARACTERIZATION OF THE HUMAN EXCISION REPAIR GENE ERCC-1: CDNA CLONING AND AMINO ACID HOMOLOGY WITH THE YEAST DNA REPAIR GENE RAD10" CELL, MIT PRESS, CAMBRIDGE, MA,, US, vol. 44, no. 6, 28 March 1986 (1986-03-28), pages 913-923, XP009002541 ISSN: 0092-8674 figure 5	1,2,4,5, 8,12,13, 18,19, 22,24
A	KANEDA S ET AL: "STRUCTURAL AND FUNCTIONAL ANALYSIS OF THE HUMAN THYMIDYLATE SYNTHASE GENE" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 265, no. 33, 1990, pages 20277-20284, XP002247623 ISSN: 0021-9258 abstract; figure 2	1,3,4,6, 8,14,15, 20-24
	--- -/--	

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/US 01/43039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	SHIROTA Y ET AL: "ERCC1 AND THYMIDYLATE SYNTHASE MRNA LEVELS PREDICT SURVIVAL FOR COLORECTAL CANCER PATIENTS RECEIVING COMBINATION OXALIPLATIN AND FLUOROURACIL CHEMOTHERAPY" JOURNAL OF CLINICAL ONCOLOGY, PHILADELPHIA, PA, US, vol. 19, no. 23, 1 December 2001 (2001-12-01), pages 4298-4304, XP009002481 abstract page 4300, column 1, paragraph 2 -page 4303, column 2, paragraph 1; table 1 ---	1-11, 18-24
P, X	WO 01 46402 A (UNIV SOUTHERN CALIFORNIA) 28 June 2001 (2001-06-28) SEQ ID Nos 1,3 abstract -----	14-17, 20,21,23

INTERNATIONAL SEARCH REPORT

Int'l application No.
PCT/US 01/43039

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-11
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 5,6,8,22-24 (partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims 1-11 comprise a surgical step, namely-step (a) which falls under Rule 39.1 (iv) PCT. Therefore, claims 1-11 have been searched on the basis of the alleged effects.

Continuation of Box I.1

Claims Nos.: 1-11

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery

Continuation of Box I.2

Claims Nos.: 5,6,8,22-24 (partially)

The feature "oligonucleotide pair ERCC1" contained in claims 5,8,22,24 and the feature "oligonucleotide pair TS" contained in claims 6,8,23,24 are merely arbitrary designations, the technical nature of the respective oligonucleotides is not defined (Art 6 PCT). From the application it is understood, that by the term "oligonucleotide pair ERCC1" the oligonucleotides defined by SEQ ID NOs 1 and 2 is meant and by the term "oligonucleotide pair TS" the oligonucleotides defined by SEQ ID NOs 3 and 4 is meant. Therefore, claims 5,6,8,22-24 have been searched only with respect to the primer pairs defined by SEQ ID NOs 1 and 2 and SEQ ID NOs 3 and 4, respectively.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 01/43039

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5705336	A	06-01-1998	NONE	
WO 0146402	A	28-06-2001	US 6248535 B1	19-06-2001
			AU 1578501 A	03-07-2001
			CA 2394618 A1	28-06-2001
			CN 1420927 T	28-05-2003
			EP 1242594 A1	25-09-2002
			NO 20022945 A	06-08-2002
			WO 0146402 A1	28-06-2001
			US 2002009794 A1	24-01-2002
			US 2002009795 A1	24-01-2002
			US 2001029018 A1	11-10-2001